Seeking Alpha
Deep value, event-driven, dividend investing, REITs
Profile| Send Message|
( followers)  

Aggressive Growth Investors are always looking at the biopharmaceutical sector for the next biggest drug that's going to skyrocket a stock. One of the key characteristics that separate aggressive growth investors from most retail investors is their appetite for risk. That being said, I consider these two companies a bit more risky than most, even though they each have their own attractive variables.

Pluristem Therapeutics (NASDAQ:PSTI), which trades in a 52-week range of $1.98 (52-week low) to $3.66 (52-week high), had closed at $2.40/share after Friday's session. On June 19th, the company announced that its cell therapy solution demonstrates positive effectiveness when applied.

Cell therapies are traditionally delivered through intravenous, or IV, injections for systemic effect. However, Pluristem's latest findings show that its PLX cells can be effective when injected by needle, into the muscle. This opens far larger markets for treatments in a wide range of potential outpatient settings and local clinics.

Not only do I think that the results were very promising for the company, but given the company's potential EPS growth, I'm attracted to PSTI at these levels. For the June quarter, PSTI is expected to post a loss of -$0.08/share on revenue of $220,000 and for the year, analysts are expecting the company to post a loss of -$0.33/share on revenue of $830,000. Analysts are also expecting PSTI's EPS to grow at an estimated 11.1% for the quarter and 5.7% for the year. In my opinion, if the company can gain enough momentum based on the clinical trials of its PLX-PAD solution for both end stage peripheral artery disease and cardiac ischemia, potential investors could see EPS growth estimates exceeded. For those looking to establish a position in the company, I'd begin with a small position and add additional shares as earnings announcements approach.

PharmAthene, Inc. (NYSEMKT:PIP), which trades in a 52-week range of $1.07 (52-week low) to $3.35 (52-week high), closed at $1.39/share during Friday's session. On June 14th, the company announced the additional developmental progress of its next generation anthrax vaccine, SparVax.

Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer commented:

Following on the successful cGMP manufacturing of SparVax at full commercial scale, the Company has now completed final analytical testing and release of the final drug product in pre-filled syringes for future clinical evaluation. This latest achievement represents another major step forward for our SparVax program. We now know that SparVax manufactured in the United States meets all of the specifications and potency metrics necessary to begin clinical studies. SparVax has previously been evaluated in two separate Phase II clinical trials involving approximately 770 subjects.

Not only do I think that the results were very promising for the company, but given the company's potential EPS growth, I'm attracted to PIP at these levels. For the June quarter, PIP is expected to post a loss of -$0.04/share on revenue of $6.15 million dollars and for the year analysts are expecting the company to post a loss of -$0.17/share on revenue of $24.68 million dollars. Analysts are also expecting PIP's EPS to grow at an estimated 20% for the quarter and -112.5% for the year. In my opinion, if the company can gain enough momentum based on the clinical trials of its SparVax solution, potential investors could see EPS growth estimates exceeded. For those looking to establish a position in the company, I'd begin with a small position and add additional shares as earnings announcements approach.

Source: 2 Pharma Plays Trading Under $2 For The Aggressive Investor